TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18469260
Drug: Formulas containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulas containing Bifidobacterium longum BL999 + Lactobacillus rhamnosus LPR + 4 g/L GOS/SCFOS
Study: 18469260
Drug: Formulas containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulas containing Bifidobacterium longum BL999 + Lactobacillus paracasei ST11 + 4 g/L GOS/SCFOS
Study: 17319473
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg) and Niacin(ER) (500 mg) combination once daily, with dose escalation to Niacin(ER) (1000 mg) in 11 patients based on lipid parameters at 8 weeks.
Study: 10599912
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no barrier placement, vehicle PGA gel used as placebo)
Study: 1911016
Drug: Labetalol (0.15‐0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (0.15‐0.3 mg kg‐1)
Study: 6211999
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg alcuronium
Study: 6211999
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg pancuronium
Study: 6211999
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg bw Sch
Study: 6211999
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg bw lignocaine
Study: 26099755
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with adjunctive intrathecal morphine (0.1 mg)
Study: 24732169
Drug: Mixed Kinesio
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed Kinesio taping-compression treatment, performed 3 times a week for 4 weeks
Study: 11454733
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of [(14)C]linezolid 500 mg (100-microCi)
Study: 11454733
Drug: 10-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-day regimen of unlabeled linezolid 500 mg b.i.d.
Study: 11454733
Drug: Single radioactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single radioactive dose of linezolid
Study: 7525901
Drug: Intra-arterial injection
Normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial injection of 131I-iodized oil (Treated group)
Study: 30014184
Drug: EG-1962 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG-1962 (600 mg)
Study: 25678453
Drug: Oral nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nimodipine (active control)
Study: 15587331
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral hyperalimentation (TPN)
Study: 8101150
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg ondansetron
Study: 8101150
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg ondansetron
Study: 2873161
Drug: Terfenadine suspension
Normalized name: terfenadine Oral Suspension
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine suspension (30 mg twice daily for children <30 kg; 60 mg twice daily for children >30 kg)
Study: 2873161
Drug: Terfenadine suspension
Normalized name: terfenadine Oral Suspension
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine suspension
Study: 30656507
Drug: Model 3
Normalized name: Model 2004FAA Model 3-EEMK Model 3-EEMK-1 Model AA-8565 Model AA-8565-LATAM Model AWFAREMK Model CHAUTAUQUAEMK Model emk1000-10 Model FAREMK Model PMONTFAREMK Model SWEEMK Model SWEEMK-1 Model QXEMK Model G4FAREMK Model AA-8565 (excluding Miami Air) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model 3 (combination of Models 1 and 2)
Study: 29099102
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MEL) at doses of 25 mg orally every 12 hours for 12 months
Study: 23537970
Drug: Abciximab plus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab plus heparin
Study: 19785815
Drug: Metformin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin as a monotherapy
Study: 19785815
Drug: Glibenclamide as
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide as a monotherapy
Study: 16716847
Drug: Twelve Steps
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twelve Steps (TS) treatment
Study: 15525622
Drug: Gargling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gargling with povidone-iodine (2.5 mg/mL, 25 mL)
Study: 15525622
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (gargling with tap water, 25 mL)
Study: 9428831
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 x 850 mg/day)
Study: 7836511
Drug: Control cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cycle (no treatment)
Study: 30150504
Drug: One-stage full-mouth
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage full-mouth oral disinfection (FMD)
Study: 22057852
Drug: Panobinostat 20
Normalized name: panobinostat 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 20 mg twice weekly (fasting)
Study: 22057852
Drug: Panobinostat 20
Normalized name: panobinostat 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 20 mg twice weekly (high-fat breakfast)
Study: 22057852
Drug: Panobinostat 20
Normalized name: panobinostat 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 20 mg twice weekly (normal breakfast)
Study: 22057852
Drug: Panobinostat (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (overall treatment)
Study: 15924807
Drug: atenolol +
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atenolol + nitrendipine + metformin (A + N + M, n = 152)
Study: 2299213
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccines with increasing antigen concentrations
Study: 7027780
Drug: High nutrition
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High nutrition supplement (800 kcal and 40 g of protein/day)
Study: 7027780
Drug: Low nutrition
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low nutrition supplement (80 kcal/day)
Study: 31017305
Drug: Audit and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audit and feedback intervention aimed at primary care centers, involving structured quality reports on medication use and diagnosis recording, sent in 2015.
Study: 29529508
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy (DBT) skills training
Study: 26881973
Drug: Diuretic renogram
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic renogram in volatile substance abusers
Study: 22247115
Drug: Probiotics and
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics and organic acids (1 g/L in water) including Lactobacillus acidophilus, Lactobacillus casei, Streptococcus faecium, Saccharomyces cerevisiae, 1% sorbic acid, and 0.2% citric acid for 7 days (T2)
Study: 22247115
Drug: Probiotics and
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics and organic acids (1 g/L in water) for 14 days (T3)
Study: 18801576
Drug: Combined phacotrabeculectomy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined phacotrabeculectomy with adjunctive mitomycin C
Study: 17258092
Drug: 25-microg low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25-microg low-dose (LD) UCN 2
Study: 17258092
Drug: 100-microg high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-microg high-dose (HD) UCN 2
Study: 9842626
Drug: Behavioural hearing
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioural hearing tactics treatment
Study: 2678684
Drug: Antiandrogens monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiandrogens monotherapy
Study: 2678684
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with antiandrogens and castration
Study: 1102567
Drug: Glucagon (1-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (1-mg dose)
Study: 30982953
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (DEX) 3.28 μg kg-1
Study: 25277638
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus remifentanil (MR)
Study: 23719683
Drug: Oral rhPTH(1-31)NH2
Normalized name: GHRH(1-44)NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rhPTH(1-31)NH2 tablets (5 mg)
Study: 23719683
Drug: Subcutaneous teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous teriparatide (20 μg daily)
Study: 19512867
Drug: Buspirone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (60 mg orally)
Study: 19512867
Drug: Dexmedetomidine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (intravenous infusion to target plasma concentration of 0.6 ng/ml)
Study: 19512867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of buspirone and dexmedetomidine
Study: 16679090
Drug: Atorvastatin (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (group I)
Study: 15596193
Drug: Goserelin 10.8
Normalized name: goserelin 10.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 10.8 mg every 84 days
Study: 15596193
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg every 28 days
Study: 90859
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous metronidazole
Study: 7846337
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline (control)
Study: 27649551
Drug: Concurrent 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent 50 Gy (in 4 fractions) to liver
Study: 27649551
Drug: Sequential 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential 50 Gy (in 4 fractions) to liver
Study: 27649551
Drug: Concurrent 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent 50 Gy (in 4 fractions) to lung
Study: 27649551
Drug: Sequential 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential 50 Gy (in 4 fractions) to lung
Study: 27649551
Drug: Sequential 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential 60 Gy (in 10 fractions) to lung or liver
Study: 21232669
Drug: Vernakalant (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant (3 mg/kg infusion for 10 min, followed by a 15-min observation, and a second infusion of 2 mg/kg if still in AF)
Study: 21232669
Drug: Amiodarone (60-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (60-min infusion of 5 mg/kg followed by a maintenance infusion of 50 mg over an additional 60 min)
Study: 19143902
Drug: Valacyclovir 2
Normalized name: valacyclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 2 g orally twice daily for 1 day and clobetasol gel 0.05% twice daily for 3 days
Study: 15093954
Drug: Paroxetine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-40 mg) plus Pindolol (5 mg)
Study: 11428178
Drug: Wild yam
Normalized name: wild yam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild yam cream
Study: 9679620
Drug: Enalapril (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (15 mg once daily)
Study: 9679620
Drug: Captopril (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (2-4 times daily)
Study: 1793422
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural group therapy (CBGT) for a period of 3 months
Study: 1793422
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural group therapy (CBGT)
Study: 6871067
Drug: Nuelin Depot
Normalized name: Nuelin S.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuelin Depot 350 mg with antacid
Study: 6871067
Drug: Theo-Dur 300
Normalized name: Theo-Dur 300mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur 300 mg with antacid
Study: 6871067
Drug: Nuelin Depot
Normalized name: Nuelin S.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuelin Depot 350 mg without antacid
Study: 6871067
Drug: Theo-Dur 300
Normalized name: Theo-Dur 300mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur 300 mg without antacid
Study: 30775145
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of oral cephalexin
Study: 22829849
Drug: Single allogenic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single allogenic mesenchymal stem cells transplantation (MSCT) at a dose of one million MSCs per kilogram of body weight.
Study: 18823912
Drug: Barcode medication
Normalized name: ECHINACEA PURPUREA WHOLE 3 [hp_X] in 1 mL / VIROLA SEBIFERA RESIN 4 [hp_X] in 1 mL / ATROPA BELLADONNA 6 [hp_X] in 1 mL / CALCIUM SULFATE ANHYDROUS 6 [hp_X] in 1 mL / LAMB 6 [hp_X] in 1 mL / ARSENIC TRIOXIDE 8 [hp_X] in 1 mL / SILICON DIOXIDE 9 [hp_X] in 1 mL / SULFUR IODIDE 10 [hp_X] in 1 mL / CALCIUM FLUORIDE 12 [hp_X] in 1 mL / CALCIUM SULFIDE 121 [hp_X] in 1 mL / LACHESIS MUTA VENOM 12 [hp_X] in 1 mL ORAL SPRAY [Thymus Sarcode]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barcode medication administration (BCMA) system
Study: 15939922
Drug: FOLFIRI (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (irinotecan 180 mg/m(2) on day 1 with LV 100 mg/m(2) and FU 400 mg/m(2) bolus, FU 600 mg/m(2) infusion)
Study: 15939922
Drug: FOLFOX4 (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 (oxaliplatin 85 mg/m(2) on day 1 with LV5FU2 regimen)
Study: 30348460
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg on day 0, 10 mg on day 1, 5 mg on day 2)
Study: 23830536
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard treatment only)
Study: 26231498
Drug: Psilocybin (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (moderate dose)
Study: 24494286
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus warm needling therapy (EA + WN)
Study: 24494286
Drug: Warm needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needling therapy (WN)
Study: 10816184
Drug: Daily interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interruption of sedative infusions
Study: 17531920
Drug: Cigarette smoking
Normalized name: Cigarette smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoking (nicotine content, 0.9 mg)
Study: 14745677
Drug: Heparin surface-modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin surface-modified PMMA intraocular lenses (HSM-IOLs)
Study: 28052885
Drug: Micronutrient-fortified young-child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient-fortified young-child formula (YCF) (1.2 mg Fe/100 mL; 1.7 μg vitamin D/100 mL)
Study: 28052885
Drug: Nonfortified cow
Normalized name: Cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfortified cow milk (CM) (0.02 mg Fe/100 mL; no vitamin D)
Study: 22360365
Drug: G-Cem (GC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Cem (GC, Japan)
Study: 20060790
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cefuroxime tablet
Study: 15501926
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (acute: bolus 0.06; drip 0.02 g/kg fat-free mass)
Study: 15501926
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (chronic: 500 mg/day for 30 days)
Study: 11772423
Drug: Postmenopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmenopausal hormone replacement therapy
Study: 9788685
Drug: Cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5 mg with sustained-release pseudoephedrine (PSE) 120 mg
Study: 7658780
Drug: Controlled-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release melatonin (2 mg per night for 3 weeks)
Study: 2501598
Drug: Nitroglycerin (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (transdermal administration via Nitroderm TTS 10 for 48 hours)
Study: 20819983
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication alone
Study: 29444522
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (antipsychotic medication + psychosocial intervention)
Study: 27502589
Drug: ACEMg (β-carotene,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEMg (β-carotene, ascorbic acid, dl-α-tocopherol acetate, magnesium) administered twice daily for approximately 3 months
Study: 27502589
Drug: ACEMg treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEMg treatment
Study: 23479993
Drug: OCA7 (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA7 (omeprazole 0.04 g/day, clarithromycin 1 g/day, amoxicillin 2 g/day for 7 days)
Study: 23479993
Drug: OCA14 (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA14 (same drugs for 14 days)
Study: 23479993
Drug: OCA7L1 (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA7L1 (same drugs for 7 days + glucosaminylmuramyldipeptide 0.001 g/day for 1 day)
Study: 23479993
Drug: OCA7L10 (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA7L10 (same drugs for 7 days + glucosaminylmuramyldipeptide 0.01 g/day for 10 days)
Study: 23479993
Drug: OCA7 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCA7 with glucosaminylmuramyldipeptide 0.001 g/day
Study: 17081536
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% vaginal P gel (90 mg) administered daily
Study: 17081536
Drug: Utrogestan vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utrogestan vaginal capsules (2 x 100 mg) administered three times daily
Study: 17081536
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8% vaginal P gel
Study: 17081536
Drug: Utrogestan vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utrogestan vaginal capsules
Study: 16128936
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 7 days (E20-7d)
Study: 16128936
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg b.i.d.) with the same antibiotics for 7 days (E40-7d)
Study: 16128936
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg b.i.d.) with the same antibiotics for 10 days (E40-10d)
Study: 10465924
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg hydromorphone s.c.
Study: 10465924
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg meperidine i.m.
Study: 2259918
Drug: NOAC I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC I (high-dose cytarabine 3 g/m2/12 h on day 1 + mitoxantrone 10 mg/m2/d on days 2 and 3)
Study: 2259918
Drug: NOAC II
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC II (high-dose cytarabine 3 g/m2/12 h on days 1 and 2 + mitoxantrone 10 mg/m2/d on days 2 and 3) with rhGM‐CSF
Study: 2259918
Drug: NOAC II
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC II (high-dose cytarabine 3 g/m2/12 h on days 1 and 2 + mitoxantrone 10 mg/m2/d on days 2 and 3) without rhGM‐CSF
Study: 385094
Drug: Lithium in
Normalized name: Product containing lithium in cutaneous dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium in combination with tryptophan (Optimax)
Study: 31988481
Drug: The Daily
Normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Daily Mile intervention
Study: 31988481
Drug: The Daily
Normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Daily Mile intervention (specifically in girls)
Study: 31988481
Drug: The Daily
Normalized name: TITANIUM DIOXIDE 0.036 g in 1 mL / ZINC OXIDE 0.0234 g in 1 mL TOPICAL LOTION [SOOTHE Daily Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Daily Mile intervention (economic analysis)
Study: 28256307
Drug: Budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI 80/4.5 μg (160/9 μg) BID
Study: 28256307
Drug: Budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI 80/2.25 μg (160/4.5 μg) BID
Study: 28256307
Drug: Budesonide pMDI
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide pMDI 80 μg (160 μg) BID
Study: 23722456
Drug: 3 consecutive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 consecutive daily intratympanic injections of 4 mg/ml dexamethasone
Study: 23722456
Drug: 3 consecutive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 consecutive weekly injections of 4 mg/ml dexamethasone
Study: 15829494
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) 200 mg/m²/day orally for five consecutive days every 4 weeks